Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS: A Druggable Target in Colon Cancer Patients.

International journal of molecular sciences - 8 Apr 2022

Negri Francesca, Bottarelli Lorena, de'Angelis Gian Luigi, Gnetti Letizia

Abstract excerpt

Mutations in KRAS are among the most frequent aberrations in cancer, including colon cancer. KRAS direct targeting is daunting due to KRAS protein resistance to small molecule inhibition. Moreover, its elevated affinity to cellular guanosine triphosphate (GTP) has made the design of specific drugs challenging. Indeed, KRAS was considered 'undruggable'. KRASG12C is the most commonly mutated variant of KRAS in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Colonic Neoplasms
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 35456940
DOI: 10.3390/ijms23084120
PMCID: PMC9027058

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS: A Druggable Target in Colon Cancer Patients.PMID 35456940Read ↗

Current Strategies and Future Dimensions in the Development of KRAS Inhibitors for Targeted Anticancer Therapy.Semantic proximity Read ↗

Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities.Semantic proximity Read ↗

Targeting KRAS Oncogene for Patients With Colorectal Cancer: A New Step Toward Precision Medicine.Semantic proximity Read ↗

Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.Semantic proximity Read ↗

Drugging KRAS: current perspectives and state-of-art review.Semantic proximity Read ↗

An overview of KRAS-targeting therapies for colorectal cancer in phase I and II development.Semantic proximity Read ↗

Targeting mutant KRAS.Semantic proximity Read ↗

Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients.Semantic proximity Read ↗

Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors.Semantic proximity Read ↗

KRAS: From undruggable to a druggable Cancer Target.Semantic proximity Read ↗

Targeting KRAS mutant cancers: from druggable therapy to drug resistance.Semantic proximity Read ↗

Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.